Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients

References

• Holstiege J, Steffen A, Goffrier B, Bätzing J. [Epidemiology of multiple sclerosis a population-based, Germany-wide study] Zentralinstitut für die kassenärztliche Versorgung in Deutschland (Zi). Versorgungsatlas-Bericht Nr. 17/09. Berlin 2017. German. doi:10.20364/VA-17.09
   Google Scholar
• Capkun G, Dahlke F, Lahoz R, et al.Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US department of defense administrative claims database. Mult Scler Relat Disord. 2015;(4):546–554. doi:10.1016/j.msard.2015.08.00526590661
   PubMed Web of Science ®Google Scholar
• Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol. 2017;13(6):375–382. doi:10.1038/nrneurol.2017.3328303911
   PubMed Web of Science ®Google Scholar
• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:1–25. doi:10.1177/1352458517751049
   Web of Science ®Google Scholar
• Lo LMP, Taylor B, van der Mai I. The prevalence of comorbidities before and after the onset of multiple sclerosis compared to the general population. ECTRIMS Online Lib. 2018;11:228575.P732.
   Google Scholar
• Kuhle J, Nourbakhsh B, Grant D, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology. 2017;88:1–6. doi:10.1212/WNL.0000000000003653
   Web of Science ®Google Scholar
• Gotte M, Mayer C, Huebner J. Use of complementary and alternative medicine in patients with multiple sclerosis in Germany. Complement Ther Med. 2018;36:113–117. doi:10.1016/j.ctim.2017.12.00629458916
   PubMed Web of Science ®Google Scholar
• Harroud A, Richards JB. Mendelian randomization in multiple sclerosis: a causal role for vitamin d and obesity? Mult Scler. 2018;24(1):80–85. doi:10.1177/135245851773737329307294
   PubMed Web of Science ®Google Scholar
• Graves JS, Barcellos LF, Shao X, et al. Genetic predictors of relapse rate in pediatric MS. Mult Scler. 2016;22:1528–1535. doi:10.1177/135245851562426926769066
   PubMed Web of Science ®Google Scholar
• Rosjo E, Lossius A, Abdelmagid N, et al. Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. Mult Scler. 2017;23(3):395–402. doi:10.1177/135245851665431027325604
   PubMed Web of Science ®Google Scholar
• Rolf L, Muris AH, Mathias A, et al. Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Mult Scler. 2017 [ Epub ahead of print]. doi:10.1177/1352458517722646
   Web of Science ®Google Scholar
• Ascherio A, Munger KL. Epidemiology of multiple sclerosis: from risk factors to prevention-an update. Semin Neurol. 2016;36(2):103–114. doi:10.1055/s-0036-157969327116717
   PubMed Web of Science ®Google Scholar
• Grant WB, Whiting SJ, Schwalfenberg GK, et al. Estimated economic benefit of increasing 25-hydroxyvitamin D concentrations of Canadians to or above 100 nmol/l. Dermatoendocrinol. 2016;8:e1248324. doi:10.1080/19381980.2016.124832427942348
   PubMed Web of Science ®Google Scholar
• Zittermann A. The estimated benefits of vitamin D for Germany. Mol Nutr Food Res. 2010;54(8):1164–1171. doi:10.1002/mnfr.20090049420373291
   PubMed Web of Science ®Google Scholar
• Jetté N, Amoozegar F, Patten SB. Depression in epilepsy, migraine, and multiple sclerosis. Neurol Clin Pract. 2017;7(2):118–127. doi:10.1212/CPJ.000000000000034929185533
   PubMedGoogle Scholar
• Marrie RA, Hanwell H. General health issues in multiple sclerosis: comorbidities, secondary conditions, and health behaviors. Mult Scler. 2013;19(4):1046–1057.23334316
   PubMed Web of Science ®Google Scholar
• Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. BJPsych. 2013;202(2):100–107. doi:10.1192/bjp.bp.111.10666623377209
   PubMedGoogle Scholar
• McKay KA. Association between psychiatric comorbidity and disability progression of multiple sclerosis. Ectrims. 2017;26;2017:202458.
   Google Scholar
• Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Neurology. 2014;82:174–181. doi:10.1212/WNL.000000000000001324376275
   PubMed Web of Science ®Google Scholar
• Marrie RA, Reingold S, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015;21(3):305–317. doi:10.1177/135245851456448725583845
   PubMed Web of Science ®Google Scholar
• Kalron A, Aloni R. Contrasting relationship between depression, quantitative gait characteristics and self-report walking difficulties in people with multiple sclerosis. Mult Scler Rel Dis. 2018;19:1–5. doi:10.1016/j.msard.2017.10.012
   PubMed Web of Science ®Google Scholar
• Piehl F, Kockum I, Khademi M, et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult Scler. 2018;24(8):1046-1054.
   Web of Science ®Google Scholar
• Sandberg L, Bistro M, Salzer J, et al. Vitamin D and axonal injury in multiple sclerosis. Mult Scler. 2016;22:1027–1031. doi:10.1177/135245851560698626462862
   PubMed Web of Science ®Google Scholar
• Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–457. doi:10.1016/j.biopsych.2009.09.03320015486
   PubMed Web of Science ®Google Scholar
• Parker GB, Brotchie H, Graham RK. Vitamin D and depression. J Affect Disord. 2017;208:56–61. doi:10.1016/j.jad.2016.08.08227750060
   PubMed Web of Science ®Google Scholar
• Nourbakhsh B, Julian L, Waubant E. Fatiuge and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study. Eur J Neurol. 2016;23(9):1482–1486. DOI:10.1111/ene.13102.27416110
   PubMed Web of Science ®Google Scholar
• Berridge MJ. Vitamin D and depression: cellular and regulatory mechanisms. Pharmacol Rev. 2017;69(2):80–92. doi:10.1124/pr.116.01322728202503
   PubMed Web of Science ®Google Scholar
• Wong SH, Chjin KY, Ima-Nirwana S. Vitamin D and depression: the evidence from an indirect clue to treatment strategy. Curr Drug Targets. 2017; (Epub ahead of print) doi:10.2174/1389450118666170913161030
   Web of Science ®Google Scholar
• Parrish JB, Weinstock-Guttman B, Smerbeck A, et al. Fatigue and depression in children with demyelinating disorders. J Child Neurol. 2012;28(6):713–718. doi:10.1177/088307381245075022805247
   PubMed Web of Science ®Google Scholar
• Högberg G, Gustafsson SA, Hällström T, et al. Depressed adolescents in a case-series were low in vitamin D and depression was ameliorated by vitamin D supplementation. Acta Paediatr. 2012;101:779–783. doi:10.1111/j.1651-2227.2012.02655.x22372707
   PubMed Web of Science ®Google Scholar
• Faissner S, Mishra M, Kaushik DK, et al. Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic. Nat Commun. 2017;8. doi:10.1038/s41467-017-02119-6
   Web of Science ®Google Scholar
• Tettey P, Siejka D, Simpson S Jr, et al. Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis. Neuroepidemiology. 2016;46(2):106–113. doi:10.1159/00044220326784322
   PubMed Web of Science ®Google Scholar
• Kowalec K, McKay KA, Patten SB, et al. Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study. Neurology. 2017 [ Epub ahead of print].
   Web of Science ®Google Scholar
• Laroni A, Signori A, Maniscalco GT, et al. Assessing association of comorbidities with treatment choice and persistence in MS. Neurology. 2017 [ (Published online before print)]. doi:10.1212/WNL.0000000000004686
   Web of Science ®Google Scholar
• Thormann A, Soelberg Sorensen P, Koch-Henriksen N, et al. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology. 2017;89(16):1668–1675. doi:10.1212/WNL.000000000000450828931645
   PubMed Web of Science ®Google Scholar
• Manouchehrinia A, Edwards LJ, Roshanisefat H, et al. Multiple sclerosis course and clinical outcomes in patients with comorbid asthma: a survey study. BMJ Open. 2015;5(5):e007806. doi:10.1136/bmjopen-2015-007806
   Web of Science ®Google Scholar
• Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D supplementation to prevent asthma exacerbations. A systematic review and meta-analysis of individual participant data. Lancet Respir Med. 2017. doi:10.1016/S2213-2600(17)30306-5
   Web of Science ®Google Scholar
• Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017:356 i6583 Published 15 February 2017 DOI:10.1136/bmj.i6583
   Web of Science ®Google Scholar
• Helde-Frankling M, Björkhem-Bergman L. Vitamin D in Pain Management. Int J Mol Sci. 2017;18:2170–2179. doi:10.3390/ijms18102170
   Web of Science ®Google Scholar
• Bazelier MT, van TP S, Uitdehaag BMJ, et al. Risk of fractures in patients with multiple sclerosis. Neurology. 2012;78(24):1967–1973. doi:10.1212/WNL.0b013e318259e0ff22592374
   PubMed Web of Science ®Google Scholar
• Wu J, Shang DE, Yang S, et al. Assoziation zwischen dem Vitamin-D-Rezeptor-Genpolymorphismus und Osteoporose. Biomed Rep. 2016;5(2):233–236. doi:10.3892/br.2016.69727446548
   PubMedGoogle Scholar
• Marrie RA, Cutter G, Tyry T, et al. A cross-sectional study of bone health in multiple sclerosis. Neurology. 2009;73:1394–1398. doi:10.1212/WNL.0b013e3181beece819858462
   PubMed Web of Science ®Google Scholar
• Simonsen SC, Celius EG, Brunborn C, et al. Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease- a case control study. BMC Neurol. 2016;16:252.27919248
   PubMed Web of Science ®Google Scholar
• Moen SM, Celius EG, Sandvik L, et al. Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a populations-based case-control study. PLoS. 2012;7(9):e45703. doi:10.1371/journal.pone.0045703
   Web of Science ®Google Scholar
• Bazelier MT, van Staa TP, Uitdehaag BM, et al. Risk of fractures in patients with multiple sclerosis. A population-based study examining the risk of fracture in patients with MS, leading to the development of a novel method of estimating fracture risk in this population. Neurology. 2012;78(24):1967–1973. doi:10.1212/WNL.0b013e318259e0ff22592374
   PubMed Web of Science ®Google Scholar
• Dobson R, Cock HR, Brex P, Giovannoni G. Vitamin D supplementation. Pract Neurol. 2018;18(1):35–42.
   Google Scholar
• Binks S, Dobson R. Risk factors, epidemiology and treatment strategies for metabolic bone disease in patients with neurological disease. Curr Osteoporos Rep. 2016.
   Web of Science ®Google Scholar
• Holmoy T, Torkildsen O, Myhr K-M, et al. Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. Acta Neurol Scand Suppl. 2012;195:63–69. doi:10.1111/ane.12028
   Google Scholar
• Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–1930. doi:10.1210/jc.2011-038521646368
   PubMed Web of Science ®Google Scholar
• Kramer J, Diehl A, Lehnert H. Epidemiological study on the dimension of vitamin D deficiency in North Germany. Dtsch Med Wochenschr. 2014;139:470–475. doi:10.1055/s-0033-136007324570191
   PubMed Web of Science ®Google Scholar
• Shipton EE, Shipton EA. Vitamin D deficiency and pain: clinical evidence of low levels of vitamin D and supplementation on chronic pain states. Pain Ther. 2015;4:67–87. doi:10.1007/s40122-015-0036-825920326
   PubMed Web of Science ®Google Scholar
• Gaikwad M, Vanlint S, Moseley GL. Factors associated with vitamin D testing, deficiency, intake, and supplementation in patients with chronic pain. J Diet Suppl. 2017; (Epub ahead of print). doi:10.1080/19390211.2017.1375060
   Google Scholar
• Amerongen van BM, Feron F. Effect of high-dose vitamin D3 intake on ambulation, muscular pain and bone mineral density in a women with multiple sclerosis: a 10-year longitudinal case report. Int J Mol Sci. 2012;13(10):13416–13483. doi:10.3390/ijms131013461
   Web of Science ®Google Scholar
• Von Kanel R, Muller-Hartmannsgruber V, Kokinogenis G, et al. Vitamin D and central hypersensitivity in patients with chronic pain. Pain Med. 2014. doi:10.1111/pme.12454
   Web of Science ®Google Scholar
• Martin KR, Reid DM. Is there a role for vitamin D in the treatment of chronic pain? Ther Adv Musculoskelet Dis. 2017(6):131–135. Published online 2017 May 9. doi:10.1177/1759720X1770812428620421
   PubMed Web of Science ®Google Scholar
• Hollis BW. Short-term and long-term consequences and concerns regarding valid assessment of vitamin D deficiency: comparison of recent food supplementation and clinical guidance reports. Curr Opin Clin Nutr Metab Care. 2011;14:598–604. doi:10.1097/MCO.0b013e32834be79821934610
   PubMed Web of Science ®Google Scholar
• Balvers MG, Brouwer-Brolsma EM, Endenburg S. Recommended intakes of vitamin D to optimize health, associated circulation 25-hydroxyvitamin D concentrations, and dosing regimens to treat deficiency: workshop report and overview of current literature. J Nutr Sci. 2015;4:e23. doi:10.1017/jns.2015.1026090099
   PubMed Web of Science ®Google Scholar
• Marziniak M. Kopfschmerzen und Multiple Sklerose. Nervenheilkunde. 2011;7:461–540.
   Google Scholar
• Villani V, De Giglio L, Sette G, et al. Determinants of the severity of comorbid migraine in multiple sclerosis. Neurol Sci. 2012;33(6):1345–1353. doi:10.1007/s10072-012-1119-522644131
   PubMed Web of Science ®Google Scholar
• Pakpoor J, Handel AE, Giovannoni G, et al. Meta-analyses of the relationship between multiple sclerosis and migraine. PLoS One. 2012;7(9):e45295. doi:10.1371/journal.pone.004529523024814
   PubMed Web of Science ®Google Scholar
• Gelfand AA, Gelfand JM, Goadsby PJ. Migraine and multiple sclerosis: epidemiology and approach to treatment. Mult Scler Relat Disord. 2013;2(2):73–79. doi:10.1016/j.msard.2012.10.00325877626
   PubMed Web of Science ®Google Scholar
• Buettner C, Rony-Reuven N, Bertisch SM, et al. Simvastatin and vitamin D for migraine prevention: a randomized controlled trial. Ann Neurol. 2015;78(6):970–981. doi:10.1002/ana.2453426418341
   PubMed Web of Science ®Google Scholar
• Scherder R, Kant N, Wolf E, et al. Psychiatric and physical comorbidities and pain in patients with multiple sclerosis. J Pain Res. 2018;11:325–334. doi:10.2147/JPR.S14671729491716
   PubMed Web of Science ®Google Scholar
• Houtchens MK, Edwards NC, Schneider G, et al. Pregnancy rates and outcomes in women with and without MS in the United States. Neurology. 2018. doi:10.1212/WNL0000000000006384
   Web of Science ®Google Scholar
• Wagner CL, Baggerly C, McDonell S, et al. Post-hoc analysis of vitamin D status and reduced risk of preterm birth in two vitamin D pregnancy cohorts compared with South Caroline March of Dimes 2009-2011 rates. J Steroid Biochem Mol Biol. 2016;155:245–251. doi:10.1016/j.jsbmb.2015.10.02226554936
   PubMed Web of Science ®Google Scholar
• Hollis BW, Wagner CL. Vitamin D supplementation during pregnancy: improvements in birth outcomes and complications through direct genomic alteration. Mol Cell Endocrinol. 2017;453:113–130. doi:10.1016/j.mce.2017.01.03928188842
   PubMed Web of Science ®Google Scholar
• Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol. 2008;194(1–2):7–17. doi:10.1016/j.jneuroim.200718177949
   PubMed Web of Science ®Google Scholar
• Balbuena LD, Middleton RM, Tuite-Dalton K, et al. Sunshine, sea, and season of birth: MS incidence in Wales. Plose One. 2016.
   Web of Science ®Google Scholar
• Cantorna MT. Vitamin D and multiple sclerosis: an update. Nutr Rev. 2008;66(10Suppl 2):S135–8. pmid:18844840; PubMed Central PMCID: PMCPMC3712128. doi:10.1111/j.1753-4887.2008.00097.x18844840
   PubMed Web of Science ®Google Scholar
• Hartl C, Obermeier V, Gerdes LA, et al. Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients. J Neurol Sci. 2017;375:160–164. doi:10.1016/j.jns.2017.01.05928320120
   PubMed Web of Science ®Google Scholar
• Miclea A, Miclea M, Pistor M, et al. Vitamin D supplementation differentially affects seasonal multiple sclerosis disease activity. Brain Behav. 2017;7(8):e00761. doi:10.1002/brb3.76128828221
   PubMed Web of Science ®Google Scholar
• Holmoy T, Rosjo E, Zetterberg H, et al. Vitamin D supplementation and neurofilament light chain in multiple sclerosis. Acta Neurol Scand. 2018. doi:10.1111/ane.13037
   Web of Science ®Google Scholar
• Hubeish M, Husari H, Itani SE, et al. Maternal vitamin D level and rate of primary cesarean section. J Clin Gynecol Obstet. 2018;7(2):43–51. doi:10.14740/jcgo473w
   Google Scholar
• Merewood A, Mehta SD, Chen TC, Bauchner H, Holick MF. Association between vitamin D deficiency and primary cesarean section. J Clin Endocrinol Metab. 2009;94(3):940–945. doi:10.1210/jc.2008-121719106272
   PubMed Web of Science ®Google Scholar
• Saul A, Dance G, Simpson S, et al. Negative, but not positive stressful life events are associated with depression, anxiety and fatigue in people with MS.   Mult Scler. 2016;22:(S3);706–827, EP1372.
   Google Scholar
• Janssen AB, Savory KA, Garay SM, et al. Persistente of anxiety symptoms after elective caesarean delivery. BJPsych Open. 2018;4(5):354–360. doi:10.1192/bjo.2018.4830202597
   PubMed Web of Science ®Google Scholar
• Ogino M, Shiozawa A, Ota H, Okamoto S, Hiroi S, Kawachi I. Treatment and comorbidities of multiple sclerosis in an employed population in Japan: analysis of health claims data. Neurodegener Dis Manag. 2018;8:2. doi:10.2217/nmt-2017-0047
   Web of Science ®Google Scholar
• Koudriavtseva T, Renna R, Plantone D, Mandoj C, Piattella MC, Giannarelli D. Association between Anemia and Multiple Sclerosis. Eur Neurol. 2015;73(3–4):233–237. doi:10.1159/00038121225823947
   PubMed Web of Science ®Google Scholar
• Smith EM, Tangpricha V. Vitamin D and anemia: insights into an emerging association. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):432–438. doi:10.1097/MED.000000000000019926414080
   PubMedGoogle Scholar
• Boehlen F, Hohlfeld H, Extermann P, et al. Platelet count at term pregnancy: a reappraisal of the threshold. Obstet Gynecol. 2000;95:30.
   Web of Science ®Google Scholar
• Gernsheimer T, James AH, Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013;121:38–47. doi:10.1182/blood-2012-08-44894423149846
   PubMed Web of Science ®Google Scholar
• Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analysis of administrative data. J Thromb Haemost. 2006;4:2377–2383. doi:10.1111/j.1538-7836.2006.02147.x16869934
   PubMed Web of Science ®Google Scholar
• Kirby S, Brown MG, Muray TJ, et al. Progression of multiple sclerosis in patients with other autoimmune disorders [P128]; Prevalence of other autoimmune diseases in patients with multiple sclerosis [P129]. Mult Scler. 2005;11:S28–S9.
   Google Scholar
• [No authors listed]. Practice Bulletin No 166: Thrombocytopenia in Pregnancy. Obstet Gynecol. 2016:128(3):e43–53.
   Google Scholar
• Bergmann F, Rath W. The differential diagnosis of thrombocytopenia in pregnancy-an interdisciplinary challenge. Dtsch Arztebl Int. 2015;112:795–802. doi:10.3238/arztebl.2015.079526634939
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Zaninoni A, Gianotta JA, Binda F, Cortelezzi A, Barcellini W. Reduced 25-OH vitamin D in patients with autoimmune cytopenias, clinical correlations and literature review. Autoimmun Rev. 2016;15:770–775. doi:10.1016/j.autrev.2016.03.01526988993
   PubMed Web of Science ®Google Scholar
• Bockow B, Bockow-Kaplan T. Refractory immune thrombocytopenia successfully treated with high-dose vitamin D supplementation and hydroxychloroquine: two case reports. J Med Case Rep. 2013;7:91.23556539
   PubMedGoogle Scholar
• Schwalfenberg GK. Solar radiation and vitamin D: mitigating environmental factors in autoimmune disease. J Environ Publ Health. 2012. doi:10.1155/2012/619381
   Google Scholar
• Liu W, Li H, Hao Y, et al. Decreased immunosuppressive actions of 1-Alpha-25-dihydroxyvitamin D3 in patients with immune thrombocytopenia. Mol Immunol. 2016;78:89–97. doi:10.1016/j.molimm.2016.08.01427614264
   PubMed Web of Science ®Google Scholar
• Morrow SA. Anxiety is more important than depression in MS- yes. Mult Scler. 2018.
   Web of Science ®Google Scholar
• Giovannoni G. Should we rebrand multiple sclerosis a dementia? Mult Scler Relat Disord. 2017;12:79–81. doi:10.1016/j.msard.2017.01.00828283112
   PubMed Web of Science ®Google Scholar
• Gasim M, Bernstein CN, Graff LA, et al. Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2918;26:124–156. doi:10.1016/j.msard.2018.09.008
   Google Scholar
• Fiest KM, Fisk JD, Patten SB, et al. Comorbidity is associated with pain-related activity limitations in multiple sclerosis. Mult Scler Relad Disord. 2015;4:470–476. doi:10.1016/j.msard.2015.07.014
   Web of Science ®Google Scholar
• Cortese M, Munger KL, Martinez-Lapiscina EH et al. Vitamin D, smoking, EBV and long-term cognitive performance among CIS patients: 11 year follow-up of BENEFIT. Presented at 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2018, Oct 12, Abstract 321.online Library, 232074.
   Google Scholar
• Pettersen JA. Does high dose vitamin D supplementation enhance cognition? A randomized trial in healthy adults. Exp Gerontol. 2017;90:90–97.28167237
   PubMed Web of Science ®Google Scholar
• Gross JH, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. Neuropsychiatr Dis Treat. 2017;13:1349–1357.28572730
   PubMed Web of Science ®Google Scholar
• Lassmann H. Targets of therapy in progressive MS. Mult Scler. 2017;23(12):1593–1599.29041864
   PubMed Web of Science ®Google Scholar
• Kappos L, Bar-Or A, Cree PAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study. Lancet. 2018;391(10127):1263–1273.29576505
   PubMed Web of Science ®Google Scholar
• Pihl-Jensen G, Tsarkiri A, Frederiksen JL. Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs. 2015;29(4):277–291.25795002
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA. Simvastatin and cognition in multiple sclerosis. Lancet Neurol. 2017;16:572–573. doi:10.1016/S1474-4422(17)30162-X28600188
   PubMed Web of Science ®Google Scholar
• Chan D, Binks S, Nicholas JM, et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomized, placebo-controlled trial. Lancet Neurol. 2017;16:591–600. doi:10.1016/S1474-4422(17)30113-828600189
   PubMed Web of Science ®Google Scholar
• Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomized, placebo-controlled, phase 2 trial. Lancet. 2014;383:2213–2221. doi:10.1016/S0140-6736(13)62242-424655729
   PubMed Web of Science ®Google Scholar
• Muris AH, Rolf L, Broen K, et al. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis. J Steroid Biochen Mol Biol. 2016;164:254–257. doi:10.1016/j.jsbmb.2015.11.009
   PubMed Web of Science ®Google Scholar
• Mowry EM, Waubant E, McCulloch C, et al. Vitamin D status predicts new brain MRI activity in multiple sclerosis. Ann Neurol. 2012;72(2):234–240. doi:10.1002/ana.2359122926855
   PubMed Web of Science ®Google Scholar
• Fitzgerald KC, Munger KL, Köchert K, et al. Association of vitamin D levels with multiple sclerosis activity and progression in patients receiving interferon beta-1b. JAMA Neurol. 2015;72(12):1458–1465. doi:10.1001/jamaneurol.2015.274226458124
   PubMed Web of Science ®Google Scholar
• Shoemaker TJ, Mowry EM. A review of vitamin D supplementation as disease-modifying therapy. Mult Scler. 2018;24(1):6–11. doi:10.1177/1352458517738131
   Web of Science ®Google Scholar
• Pettersen JA. Vitamin D and executive functioning: are higher levels better? J Clin Exp Neuropsychol. 2016;38(4):467–477. doi:10.1080/13803395.2015.112545226708262
   PubMed Web of Science ®Google Scholar
• Miller KM, Hart PH, de Klerk NH, Davis EA, Lucas RM. Are low sun exposure and/or vitamin D risk factors for type 1 diabetes?. Photochem Photoviol Sci. 2017;16:381. doi:10.1039/C6PP00294C
   Web of Science ®Google Scholar
• Elmets CA, Cala CM, Xu H. Photoimmunology. Dermatol Clin. 2014;32:277–290. doi:10.1016/j.det.2014.03.00524891051
   PubMed Web of Science ®Google Scholar
• Fajuyigbe D, Young AR. The impact of skin colour on human photobiological responses. Pigment Cell Melanoma Res. 2016;29(6):607–618. doi:10.1111/pcmr.1251127454804
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Lucas R, Xiang AH, et al. MS sunshine study: sun exposure but not vitamin D Is associated with multiple sclerosis risk in blacks and hispanics. Nutrients. 2018;10(3):pii:E268. doi:10.3390/nu10030268
   Web of Science ®Google Scholar
• Rito Y, Flores J, Fernández-Aguilar A, et al. Vitamin D and disability in relapsing-remitting multiple sclerosis in patients with a Mexican background. Acta Neurol Belg. 2018;118(1):47–52. doi:10.1007/s13760-017-0834-328975580
   PubMed Web of Science ®Google Scholar
• Razaz N, Joseph KS, Boyce WT, et al. Children of chronically ill parents: relationship between parental multiple sclerosis and childhood development health. Mult Scler. 2016;22(11):1452–1462. doi:10.1177/135245851562162426683589
   PubMed Web of Science ®Google Scholar
• Moberg JY. Live course of children with parental multiple sclerosis. Dan Med J. 2017;Aug;64(8) pii. B5399.
   Web of Science ®Google Scholar
• Carlberg C, Haq A. The concept of the personal vitamin D response index. J Steroid Biochemist Mol Biol. 2018;175:12–17. doi:10.1016/j.jsbmb.2016.12.011
   Web of Science ®Google Scholar
• Pierrot-Deseilligny CH, Souberbielle JD. Vitamin D and multiple sclerosis: an update. Mult Scler Rel Disord. 2017;14:35–45. doi:10.1016/j.msard.2017.03.014
   PubMed Web of Science ®Google Scholar
• Saleh L, Tang J, Gawinecka J, et al. Impact of a single oral dose of 1000,000IU vitamin D3 on profiles of serum 25(OH)D3 and its metabolites 24,25(OH)2D3 3-epi-25(OH)D3, and 1,25(OH)2D3 in adults with vitamin D insufficiency. Clin Chem Lab Med. 2017;55(12):1912–1921. doi:10.1515/cclm-2016-112928328526
   PubMed Web of Science ®Google Scholar
• Rassaque M. Can adverse effects of excessive vitamin D supplementation occur without developing hypervitaminosis D? J Steroid Biochem Mol Biol. 2017. doi:10.1016/j.jsbmb.2017.07.006
   Web of Science ®Google Scholar
• Kimbal SM, Ursell MR, O´Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007;86:645–651. doi:10.1093/ajcn/86.3.64517823429
   PubMed Web of Science ®Google Scholar
• Valcour A, Blocki F, Hawkins DM, et al. Effects of age and serum 25(OH)-vitamin D on serum parathyroid hormone levels. J Endocrinol Metab. 2012;97(11):398–3995. doi:10.1210/jc.2012-2276
   Web of Science ®Google Scholar
• Wiendl H, Schwab N, Breuer JH. High-dose vitamin D as adjunctive therapy in the treatment of multiple sclerosis? - an update. German multiple sclerosis society (DMSG), disease-related competence network (KKNMS) [press information]. 2017 Available from https://www.dmsg.de/multiple-sklerose.../hochdosiertes-vitamin-d-als-zusatztherapie-in-derBehandlung-der-multiplen-Sklerose-ein-. Accessed 22 May, 2019.
   Google Scholar
• Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88(suppl):582S–6S. doi:10.1093/ajcn/88.2.582S18689406
   PubMed Web of Science ®Google Scholar
• Jelinek GA, Marck CH, Weiland TJ, et al. Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis. BMC Neurol. 2015;15:132. doi:10.1186/s12883-015-0394-126243188
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Raj B, Ramanathan M, et al. Autoimmune comorbidities are associated with brain injury in multiple sclerosis. Am J Neuroradiol. 2016;37:1010–1016. doi:10.3174/ajnr.A468126892983
   PubMed Web of Science ®Google Scholar
• Kalb R, Beier M, Benedict RH, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler. 2018. doi:10.1177/1352458518803785
   Web of Science ®Google Scholar
• Rossi S, Studer V, Motta C, et al. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. Neurology. 2017;89(13). doi:10.1212/WNL.0000000000004411
   Web of Science ®Google Scholar
• Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Neurology. 2014;82:174–181. doi:10.1212/WNL.000000000000001324376275
   PubMed Web of Science ®Google Scholar
• Patten SB, Svenson LW, Metz LM. Psychotic disorders in MS: population-based evidence of an association. Neurology. 2005;65:1123–1125. doi:10.1212/01.wnl.0000178998.95293.2916217073
   PubMed Web of Science ®Google Scholar
• Degurud E, Nygard O, de Vogel ST, et al. Plasma 25-hydroxyvitamin D and mortalität in patients with suspected stable angina pectoris. J Clin Endocrinol Metab. 2018;103(3):1161–1170. doi:10.1210/jc.2017-0232829325121
   PubMed Web of Science ®Google Scholar
• Marrie RA, Daumer M. A gestational dose of vitamin D per day keeps the MS doctor away. Neurology. 2017;88:1. doi:10.1212/WNL.0000000000003693
   Web of Science ®Google Scholar
• Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: a comprehensive review. Neurol Ther. 2018;7(1):59–85. doi:10.1007/s40120-017-0086-429243029
   PubMed Web of Science ®Google Scholar
• Schlögl M, Holick M. Vitamin D an neurocognitive function. Clin Interv Aging. 2014;9:559–568.24729696
   PubMed Web of Science ®Google Scholar
• Spiro A, Buttress JL, Vitamin D. An overview of vitamin D status and intake in Europe. Nutr Bull. 2014;39:322–350.25635171
   PubMedGoogle Scholar
• Marck CD, Neate SL, Taylor KL, et al. Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors. PLoS One. 2016;11(2):e0148573. doi:10.1371/journal.pone.014857326849357
   PubMed Web of Science ®Google Scholar
• Marrie RA, Walld R, Bolton JM, et al. Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. Gen Hosp Psychiatry. 2018;53:65–72. doi:10.1016/j.genhosppsych.2018.06.00129929117
   PubMed Web of Science ®Google Scholar
• Panda SP, Das RC, Srivastava K, et al. Psychiatric comorbidity in multiple sclerosis. Neurol Neurochir Pol. 2018. doi:10.1016/pjnns.2018.09.003
   Web of Science ®Google Scholar
• Zettl U, Eichstadt K, Ellenberger D et al. MS in Deutschland: Symptome und Behandlungsdefizite. [MS in Germany: symptoms and treatment deficits]. NeuroTransmitter. 2018;29(6):42–44. German.
   Google Scholar
• Sedal L, Winkel A, Laing J, et al. Current concepts in multiple sclerosis therapy. Degener Neurol Neuromuscul Dis. 2017;7:109–125. doi:10.2147/DNND.S10925130050382
   PubMed Web of Science ®Google Scholar
• Edwards NC, Munsell M, Menzin J, et al. Comorbidity in US patients with multiple sclerosis. Patient Relat Outcome Meas. 2018;9:97–102. doi:10.2147/PROM.S14838729491723
   PubMed Web of Science ®Google Scholar
• Lorefice L, Fenu G, Pitzalis R, et al. Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study. J Neurol. 2018;265(5):1096–1110. doi:10.1007/s00415-018-8811-129508133
   PubMed Web of Science ®Google Scholar
• Marrie RA. Comorbidity in multiple sclerosis: implications for patient care. Nat Rev Neurol. 2017;13:375–382. doi:10.1038/nrneurol.2017.3328303911
   PubMed Web of Science ®Google Scholar
• Fond G, Godin O, Schürhoff F, et al. Hypovitaminosis D is associated with depression and anxiety in schizophrenia: results from the national FACE-SZ cohort. Psychiatry Res. 2018;270:104–110. doi:10.1016/j.psychres.2018.09.02430245372
   PubMed Web of Science ®Google Scholar
• McLaughlin L, Clarke L, Khalilidehkordi E, et al. Vitamin d for the treatment of multiple sclerosis. A meta-analysis. J Neurol. 2018. doi:10.1007/s00415-018-9074-6
   Web of Science ®Google Scholar